Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,484 | 2,086 | 1,335 | 4,092 | 6,699 |
| Marketable Securities | 52,634 | 68,351 | 82,278 | 92,232 | 99,569 |
| TOTAL | $55,703 | $70,975 | $84,365 | $97,509 | $109,101 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 22 | 54 | 43 | 43 | 48 |
| TOTAL | $22 | $54 | $43 | $43 | $48 |
| Total Assets | $55,725 | $71,029 | $84,408 | $97,552 | $109,149 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,346 | 4,175 | 5,189 | 3,506 | 2,857 |
| Accrued Expenses | 5,741 | 5,362 | 7,173 | 8,689 | 5,566 |
| TOTAL | $8,087 | $9,537 | $12,362 | $12,195 | $8,422 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 13 | 0 | 0 | 0 | 0 |
| TOTAL | $13 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $8,099 | $9,537 | $12,362 | $12,195 | $8,422 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 30,174 | 30,174 | 30,174 | 30,174 | 30,099 |
| Common Shares | 30 | 30 | 30 | 30 | 30 |
| Retained earnings | -622,225 | -600,499 | -582,731 | -560,903 | -535,738 |
| TOTAL | $47,625 | $61,492 | $72,046 | $85,357 | $100,727 |
| Total Liabilities And Equity | $55,725 | $71,028 | $84,408 | $97,552 | $109,149 |